EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

False positive plasma p‐tau217 results associated with heterophilic antibody interference: A potential clinical pitfall

Alicia Algeciras-Schimnich iD, J Paul Theobald, Daniel J Figdore, Susan Ashrafzadeh Kian, Joshua A Bornhorst

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.71045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Alicia Algeciras-Schimnich und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: tau Proteins, Alzheimer Disease, Antibodies, Heterophile. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Plasma phosphorylated tau at threonine 217 (p‐tau217) has emerged as one of the most promising blood‐based biomarkers for Alzheimer's disease (AD). While rare, heterophilic antibodies (HAb) are a persistent potential confounding factor in immunoassays. METHODS Potential HAb interference in the Lumipulse G pTau217 assay in samples exhibiting concentrations > 10 pg/mL were investigated. Samples were subjected to HAb blocking reagent (HBT), and in some cases, polyethylene glycol (PEG) precipitation and serial dilutions. RESULTS In 14 of the 15 suspected HAb cases, HBT treatment greatly reduced measured p‐tau217 concentrations. and in one of three specimens selected for further investigation, reduced Aβ42 concentrations PEG precipitation in the three selected samples also reduced p‐tau217 concentrations, while serial dilution yielded mixed effects. Control specimens were unaffected by sample treatment or dilutions. DISCUSSION HAb may result in falsely elevated p‐tau217 and p‐tau217/Aβ42 ratio. HAb interference should be considered in cases of unusually high p‐tau217 concentrations prior to clinical interpretation. Highlights Potential heterophile antibody (HAb) interference in the Lumipulse p‐tau217 immunoassay was investigated. Investigation was performed using HAb blocking reagent, and in some cases also using PEG precipitation . Patients with p‐tau217 concentrations > 10 pg/mL exhibited positive HAb interference in 14 of 15 cases. HAb interference can lead to falsely positive p‐tau217/Aβ42 ratios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAlzheimer DiseaseAntibodies, HeterophileHumansFalse Positive ReactionsAmyloid beta-PeptidesBiomarkersImmunoassayPhosphorylationFemaleMaleAgedPeptide Fragments

Stichwörter der Autor:innen

Fujirebio Lumipulse p‐tau217Heterophilic antibodiesImmunoassays

Substanzen

tau ProteinsAntibodies, HeterophileAmyloid beta-PeptidesBiomarkersMAPT protein, humanamyloid beta-protein (1-42)Peptide Fragments

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Alicia Algeciras-Schimnich

Zitieren

APA

Algeciras-Schimnich, A., Theobald, J. P., Figdore, D. J., Ashrafzadeh Kian, S., & Bornhorst, J. A. (2025). False positive plasma p‐tau217 results associated with heterophilic antibody interference: A potential clinical pitfall. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71045

Vancouver

Algeciras-Schimnich A, Theobald JP, Figdore DJ, Ashrafzadeh Kian S, Bornhorst JA. False positive plasma p‐tau217 results associated with heterophilic antibody interference: A potential clinical pitfall. Alzheimer's & Dementia. 2025. doi:10.1002/alz.71045

BibTeX
@article{AlgecirasSchimnich2025,
  author = {Algeciras-Schimnich, Alicia and Theobald, J Paul and Figdore, Daniel J and Ashrafzadeh Kian, Susan and Bornhorst, Joshua A},
  title = {False positive plasma p‐tau217 results associated with heterophilic antibody interference: A potential clinical pitfall},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.71045}
}
Kostenlos starten →